Clinical Long Read Genomics services for the NIAID Centralized Sequencing Program NOI-NIAID-25-2261604
Summary
AI-generated · Aug 25, 2025Provide clinical long-read genomics services for the NIAID Centralized Sequencing Program, including symptom-driven long-read sequencing analysis and targeted long-read sequencing, to support genetic testing, harmonization of phenotypic and genomic data, variant interpretation, and delivery of clinically validated results for patients enrolled in NIH Clinical Center protocols.
The effort aims to advance understanding of the genetic etiology of disease and meet the clinical need for genomic evaluations; it requires the services and industry expertise necessary to perform long-read sequencing as described in the SOW, with results that directly impact patient care and the discovery of disease mechanisms.
In support of clinical research, the NIAID Centralized Sequencing Program (CSP) is comprehensive program that obtains genetic testing, harmonizes phenotypic and genomic data, performs variant interpretation, and provides clinically validated results for patients enrolled in protocols at the NIH Clinical Center. The goal of the NIAID Centralized Sequencing Program is both to contribute to the understanding of underlying genetic etiology of disease and to address the clinical need for genomic evaluations. The purpose of this acquisition is to support the mission of DIR to obtain genetic testing for the NIAID CSP. The objective is to purchase both symptom-driven long read sequencing analysis and targeted long read sequencing. The results of this testing will have direct implications for the care of NIH patients and for the discovery of disease mechanisms. The scope of this effort includes the services and industry knowledge necessary to provide long read sequencing as specified in this SOW.
From Combined Synopsis/Solicitation posted on Aug 15, 2025Notice history
1Details
Award Information
Not yet awarded
Contacts
Phone
Agency
Place of Performance
USA